Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis

Clin Infect Dis. 2004 Apr 15;38(8):e73-5. doi: 10.1086/382675. Epub 2004 Apr 1.

Abstract

We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis. Coadministration of these agents led to a strong increase in itraconazole concentrations and a decrease in concentrations of its metabolite, hydroxyitraconazole, which is equally active pharmacologically. The dosage of itraconazole was reduced when it was used in combination with lopinavir/ritonavir.

Publication types

  • Case Reports

MeSH terms

  • AIDS-Related Opportunistic Infections / blood
  • AIDS-Related Opportunistic Infections / drug therapy
  • Antifungal Agents / blood
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Drug Interactions
  • Drug Therapy, Combination
  • HIV Infections / blood*
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • Histoplasmosis / drug therapy
  • Humans
  • Itraconazole / analogs & derivatives*
  • Itraconazole / blood
  • Itraconazole / pharmacology*
  • Itraconazole / therapeutic use
  • Lopinavir
  • Male
  • Middle Aged
  • Pyrimidinones / pharmacology
  • Pyrimidinones / therapeutic use
  • Ritonavir / pharmacology
  • Ritonavir / therapeutic use

Substances

  • Antifungal Agents
  • HIV Protease Inhibitors
  • Pyrimidinones
  • hydroxyitraconazole
  • Lopinavir
  • Itraconazole
  • Ritonavir